These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 15361919)

  • 21. Antidepressants for smoking cessation.
    Hughes JR; Stead LF; Hartmann-Boyce J; Cahill K; Lancaster T
    Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD000031. PubMed ID: 24402784
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bupropion: a review of its mechanism of antidepressant activity.
    Ascher JA; Cole JO; Colin JN; Feighner JP; Ferris RM; Fibiger HC; Golden RN; Martin P; Potter WZ; Richelson E
    J Clin Psychiatry; 1995 Sep; 56(9):395-401. PubMed ID: 7665537
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized, placebo-controlled trial of bupropion sustained release in chronic low back pain.
    Katz J; Pennella-Vaughan J; Hetzel RD; Kanazi GE; Dworkin RH
    J Pain; 2005 Oct; 6(10):656-61. PubMed ID: 16202958
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Empirically Supported Use of Psychiatric Medications in Adolescents and Adults with IBD.
    Thorkelson G; Bielefeldt K; Szigethy E
    Inflamm Bowel Dis; 2016 Jun; 22(6):1509-22. PubMed ID: 27167571
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Retrospective analysis of the health-care costs of bupropion sustained release in comparison with other antidepressants.
    Poret AW; Neslusan C; Ricci JF; Wang S; Khan ZM; Kwong JW
    Value Health; 2001; 4(5):362-9. PubMed ID: 11705126
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antidepressants for smoking cessation.
    Howes S; Hartmann-Boyce J; Livingstone-Banks J; Hong B; Lindson N
    Cochrane Database Syst Rev; 2020 Apr; 4(4):CD000031. PubMed ID: 32319681
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of fluoxetine on the ability of bupropion to modulate extracellular dopamine and norepinephrine concentrations in three mesocorticolimbic areas of rats.
    Li SX; Perry KW; Wong DT
    Neuropharmacology; 2002 Feb; 42(2):181-90. PubMed ID: 11804614
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Spotlight on bupropion in major depressive disorder.
    Dhillon S; Yang LP; Curran MP
    CNS Drugs; 2008; 22(7):613-7. PubMed ID: 18547129
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neurochemical and psychotropic effects of bupropion in healthy male subjects.
    Gobbi G; Slater S; Boucher N; Debonnel G; Blier P
    J Clin Psychopharmacol; 2003 Jun; 23(3):233-9. PubMed ID: 12826985
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Resolution of pregabalin and mirtazapine associated restless legs syndrome by bupropion in a patient with major depressive disorder.
    Park YM; Lee HJ; Kang SG; Cho JH; Kim L
    Psychiatry Investig; 2009 Dec; 6(4):313-5. PubMed ID: 20140131
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bupropion Hydrochloride Sustained Release and Diurnal Enuresis: A Previously Unreported Adverse Effect.
    Schwitalla TA; Patel RA; Catalano G; Nirmalani-Gandhy A
    Clin Neuropharmacol; 2019; 42(6):211-213. PubMed ID: 31644430
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bupropion: a new antidepressant drug, the mechanism of action of which is not associated with down-regulation of postsynaptic beta-adrenergic, serotonergic (5-HT2), alpha 2-adrenergic, imipramine and dopaminergic receptors in brain.
    Ferris RM; Beaman OJ
    Neuropharmacology; 1983 Nov; 22(11):1257-67. PubMed ID: 6320035
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The noradrenergic action in antidepressant treatments: pharmacological and clinical aspects.
    Dell'Osso B; Palazzo MC; Oldani L; Altamura AC
    CNS Neurosci Ther; 2011 Dec; 17(6):723-32. PubMed ID: 21155988
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rates of 5 common antidepressant side effects among new adult and adolescent cases of depression: a retrospective US claims study.
    Anderson HD; Pace WD; Libby AM; West DR; Valuck RJ
    Clin Ther; 2012 Jan; 34(1):113-23. PubMed ID: 22177545
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
    Hewett K; Gee MD; Krishen A; Wunderlich HP; Le Clus A; Evoniuk G; Modell JG
    J Psychopharmacol; 2010 Aug; 24(8):1209-16. PubMed ID: 19939870
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antidepressants for smoking cessation.
    Hughes J; Stead L; Lancaster T
    Cochrane Database Syst Rev; 2004 Oct; (4):CD000031. PubMed ID: 15494986
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects.
    Kennedy SH; McCann SM; Masellis M; McIntyre RS; Raskin J; McKay G; Baker GB
    J Clin Psychiatry; 2002 Mar; 63(3):181-6. PubMed ID: 11926715
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion treatment.
    Dong J; Blier P
    Psychopharmacology (Berl); 2001 Apr; 155(1):52-7. PubMed ID: 11374336
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice.
    Bourin M; Chenu F; Prica C; Hascoët M
    Psychopharmacology (Berl); 2009 Sep; 206(1):97-107. PubMed ID: 19517098
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Studies of bupropion's mechanism of antidepressant activity.
    Ferris RM; Cooper BR; Maxwell RA
    J Clin Psychiatry; 1983 May; 44(5 Pt 2):74-8. PubMed ID: 6406468
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.